PMC:7558914 / 30983-32335 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"878","span":{"begin":588,"end":602},"obj":"Gene"},{"id":"879","span":{"begin":668,"end":682},"obj":"Gene"},{"id":"880","span":{"begin":703,"end":717},"obj":"Gene"},{"id":"881","span":{"begin":738,"end":752},"obj":"Gene"},{"id":"882","span":{"begin":430,"end":435},"obj":"Gene"},{"id":"883","span":{"begin":127,"end":146},"obj":"Disease"},{"id":"884","span":{"begin":180,"end":189},"obj":"Disease"},{"id":"885","span":{"begin":200,"end":209},"obj":"Disease"},{"id":"886","span":{"begin":218,"end":227},"obj":"Disease"},{"id":"887","span":{"begin":275,"end":288},"obj":"CellLine"},{"id":"889","span":{"begin":43,"end":67},"obj":"Disease"},{"id":"892","span":{"begin":1205,"end":1224},"obj":"Chemical"},{"id":"893","span":{"begin":1271,"end":1290},"obj":"Chemical"}],"attributes":[{"id":"A878","pred":"tao:has_database_id","subj":"878","obj":"Gene:2902"},{"id":"A879","pred":"tao:has_database_id","subj":"879","obj":"Gene:2902"},{"id":"A880","pred":"tao:has_database_id","subj":"880","obj":"Gene:2902"},{"id":"A881","pred":"tao:has_database_id","subj":"881","obj":"Gene:2902"},{"id":"A882","pred":"tao:has_database_id","subj":"882","obj":"Gene:2902"},{"id":"A883","pred":"tao:has_database_id","subj":"883","obj":"MESH:D012140"},{"id":"A884","pred":"tao:has_database_id","subj":"884","obj":"MESH:D011014"},{"id":"A885","pred":"tao:has_database_id","subj":"885","obj":"MESH:D011014"},{"id":"A886","pred":"tao:has_database_id","subj":"886","obj":"MESH:D011014"},{"id":"A887","pred":"tao:has_database_id","subj":"887","obj":"CVCL:6690"},{"id":"A889","pred":"tao:has_database_id","subj":"889","obj":"MESH:C000657245"},{"id":"A892","pred":"tao:has_database_id","subj":"892","obj":"MESH:C558899"},{"id":"A893","pred":"tao:has_database_id","subj":"893","obj":"MESH:C558899"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 2 Antiviral treatment protocols for coronavirus disease 2019 according to clinical condition.\nAntiviral Treatment Mild Respiratory Illness with Clinical Risk Factors Mild Pneumonia Moderate Pneumonia Severe Pneumonia\nNo 2 (13.3%) 1 (6.7%) NR NR\nH1 5 (33.3%) NR NR NR\nH2 1 (6.7%) NR NR NR\nLR1 1 (6.7%) NR NR NR\nH1 + A 3 (20.0%) 4 (26.6%) 1 (6.7%) NR\nH2 + A 1 (6.7%) 2 (13.3%) 1 (6.7%) NR\nH3 + A NR 1 (6.7%) 2 (13.3%) 1 (6.7%)\nH4 + A NR NR 1 (6.7%) 1 (6.7%)\nH1 + LR1 2 (13.3%) 3 (20.0%) NR NR\nH1 + LR2 NR 1 (6.7%) 5 (33.3%) 3 (20.0%)\nH3 + LR1 NR NR 1 (6.7%) NR\nH3 + LR2 NR 3 (20.0%) 1 (6.7%) 4 (26.6%)\nH1 + A + LR1 NR NR 1 (6.7%) NR\nH1 + A + LR2 NR NR 1 (6.7%) NR\nH3 + A + LR1 NR NR 1 (6.7%) NR\nH3 + A + LR2 NR NR NR 6 (40.0%)\nH1: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/12 h (day 2 to 5) (regimen 1); H2: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/8 h (day 2 to 5) (regimen 2); H3: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/12 h (day 2 to 7–10) (regimen 3); H4: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/8 h (day 2 to 7–10) (regimen 4); A: Azithromycin 500 mg/24 h (day 1) + 250 mg/24 h (day 2 to 5); LR1: lopinavir/ritonavir 200/50 mg/12 h (day 1 to 5) (regimen 1); LR2: lopinavir/ritonavir 200/50 mg/12 h (day 1 to 7–10) (regimen 2); NR: not reported."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T55","span":{"begin":127,"end":146},"obj":"Phenotype"},{"id":"T56","span":{"begin":180,"end":189},"obj":"Phenotype"},{"id":"T57","span":{"begin":200,"end":209},"obj":"Phenotype"},{"id":"T58","span":{"begin":218,"end":227},"obj":"Phenotype"}],"attributes":[{"id":"A55","pred":"hp_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/HP_0002086"},{"id":"A56","pred":"hp_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A57","pred":"hp_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A58","pred":"hp_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Table 2 Antiviral treatment protocols for coronavirus disease 2019 according to clinical condition.\nAntiviral Treatment Mild Respiratory Illness with Clinical Risk Factors Mild Pneumonia Moderate Pneumonia Severe Pneumonia\nNo 2 (13.3%) 1 (6.7%) NR NR\nH1 5 (33.3%) NR NR NR\nH2 1 (6.7%) NR NR NR\nLR1 1 (6.7%) NR NR NR\nH1 + A 3 (20.0%) 4 (26.6%) 1 (6.7%) NR\nH2 + A 1 (6.7%) 2 (13.3%) 1 (6.7%) NR\nH3 + A NR 1 (6.7%) 2 (13.3%) 1 (6.7%)\nH4 + A NR NR 1 (6.7%) 1 (6.7%)\nH1 + LR1 2 (13.3%) 3 (20.0%) NR NR\nH1 + LR2 NR 1 (6.7%) 5 (33.3%) 3 (20.0%)\nH3 + LR1 NR NR 1 (6.7%) NR\nH3 + LR2 NR 3 (20.0%) 1 (6.7%) 4 (26.6%)\nH1 + A + LR1 NR NR 1 (6.7%) NR\nH1 + A + LR2 NR NR 1 (6.7%) NR\nH3 + A + LR1 NR NR 1 (6.7%) NR\nH3 + A + LR2 NR NR NR 6 (40.0%)\nH1: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/12 h (day 2 to 5) (regimen 1); H2: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/8 h (day 2 to 5) (regimen 2); H3: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/12 h (day 2 to 7–10) (regimen 3); H4: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/8 h (day 2 to 7–10) (regimen 4); A: Azithromycin 500 mg/24 h (day 1) + 250 mg/24 h (day 2 to 5); LR1: lopinavir/ritonavir 200/50 mg/12 h (day 1 to 5) (regimen 1); LR2: lopinavir/ritonavir 200/50 mg/12 h (day 1 to 7–10) (regimen 2); NR: not reported."}

{"project":"LitCovid-sentences","denotations":[{"id":"T208","span":{"begin":0,"end":100},"obj":"Sentence"},{"id":"T209","span":{"begin":101,"end":227},"obj":"Sentence"},{"id":"T210","span":{"begin":228,"end":259},"obj":"Sentence"},{"id":"T211","span":{"begin":260,"end":285},"obj":"Sentence"},{"id":"T212","span":{"begin":286,"end":310},"obj":"Sentence"},{"id":"T213","span":{"begin":311,"end":336},"obj":"Sentence"},{"id":"T214","span":{"begin":337,"end":379},"obj":"Sentence"},{"id":"T215","span":{"begin":380,"end":421},"obj":"Sentence"},{"id":"T216","span":{"begin":422,"end":463},"obj":"Sentence"},{"id":"T217","span":{"begin":464,"end":498},"obj":"Sentence"},{"id":"T218","span":{"begin":499,"end":537},"obj":"Sentence"},{"id":"T219","span":{"begin":538,"end":582},"obj":"Sentence"},{"id":"T220","span":{"begin":583,"end":613},"obj":"Sentence"},{"id":"T221","span":{"begin":614,"end":658},"obj":"Sentence"},{"id":"T222","span":{"begin":659,"end":693},"obj":"Sentence"},{"id":"T223","span":{"begin":694,"end":728},"obj":"Sentence"},{"id":"T224","span":{"begin":729,"end":763},"obj":"Sentence"},{"id":"T225","span":{"begin":764,"end":799},"obj":"Sentence"},{"id":"T226","span":{"begin":800,"end":1138},"obj":"Sentence"},{"id":"T227","span":{"begin":1139,"end":1352},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 2 Antiviral treatment protocols for coronavirus disease 2019 according to clinical condition.\nAntiviral Treatment Mild Respiratory Illness with Clinical Risk Factors Mild Pneumonia Moderate Pneumonia Severe Pneumonia\nNo 2 (13.3%) 1 (6.7%) NR NR\nH1 5 (33.3%) NR NR NR\nH2 1 (6.7%) NR NR NR\nLR1 1 (6.7%) NR NR NR\nH1 + A 3 (20.0%) 4 (26.6%) 1 (6.7%) NR\nH2 + A 1 (6.7%) 2 (13.3%) 1 (6.7%) NR\nH3 + A NR 1 (6.7%) 2 (13.3%) 1 (6.7%)\nH4 + A NR NR 1 (6.7%) 1 (6.7%)\nH1 + LR1 2 (13.3%) 3 (20.0%) NR NR\nH1 + LR2 NR 1 (6.7%) 5 (33.3%) 3 (20.0%)\nH3 + LR1 NR NR 1 (6.7%) NR\nH3 + LR2 NR 3 (20.0%) 1 (6.7%) 4 (26.6%)\nH1 + A + LR1 NR NR 1 (6.7%) NR\nH1 + A + LR2 NR NR 1 (6.7%) NR\nH3 + A + LR1 NR NR 1 (6.7%) NR\nH3 + A + LR2 NR NR NR 6 (40.0%)\nH1: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/12 h (day 2 to 5) (regimen 1); H2: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/8 h (day 2 to 5) (regimen 2); H3: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/12 h (day 2 to 7–10) (regimen 3); H4: hydroxychloroquine 400 mg/12 h (day 1) + 200 mg/8 h (day 2 to 7–10) (regimen 4); A: Azithromycin 500 mg/24 h (day 1) + 250 mg/24 h (day 2 to 5); LR1: lopinavir/ritonavir 200/50 mg/12 h (day 1 to 5) (regimen 1); LR2: lopinavir/ritonavir 200/50 mg/12 h (day 1 to 7–10) (regimen 2); NR: not reported."}